

LIGAND PHARMACEUTICALS INC

Form 8-K

April 22, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 20, 2009

**LIGAND PHARMACEUTICALS INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

|                                                                      |                                  |                                        |
|----------------------------------------------------------------------|----------------------------------|----------------------------------------|
| <b>Delaware</b><br>(State or Other Jurisdiction)                     | <b>001-33093</b><br>(Commission) | <b>77-0160744</b><br>(I.R.S. Employer) |
| of Incorporation or Organization)                                    | File Number)                     | Identification No.)                    |
| <b>10275 Science Center Drive, San Diego, California, 92121-1117</b> |                                  |                                        |
| (Address of Principal Executive Offices) (Zip Code)                  |                                  |                                        |
| <b>(858) 550-7500</b>                                                |                                  |                                        |

## Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 20, 2009, Bruce A. Peacock, a member of the Board of Directors (the **Board**) of Ligand Pharmaceuticals Incorporated (the **Company** or **Ligand**), notified the Company of his decision not to stand for re-election at our upcoming annual stockholders meeting on May 29, 2009. The decision by Mr. Peacock not to stand for re-election to the Board was not the result of any disagreement with Ligand on any matter related to the Company's operations, policies or practices.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this report to be signed on its behalf by the undersigned.

**LIGAND PHARMACEUTICALS INCORPORATED**

Date: April 22, 2009

By: /s/ Charles S. Berkman  
Name: Charles S. Berkman  
Title: Vice President, General Counsel and Secretary